MLECHealthcare · BiotechnologyMLEC Stock Forecast: Moolec Science SA Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 14 Sept 2026 — in the weakest quartile.
MLEC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Moolec Science SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Value (0): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
MLEC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MLEC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Jan 2024 | Maxim Group | Initiates | Buy | $6.00 |
| 22 Nov 2022 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 20 Oct 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Sept 2022 | Wedbush | Maintains | Outperform | — |
| 7 Sept 2022 | Capital One | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MLEC appears on the weeks it earns a place.
MLEC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Sept 2026, Moolec Science SA returned −66.8% against +16.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MLEC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Moolec Science SA (MLEC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.0×
- Price / sales
- 0.0×
- Price / book
- 9.5×
- EV / EBITDA
- −3.0×
Cheaper than 76% of US stocks
Cheaper than 99% of US stocks
Cheaper than 10% of US stocks
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- 69.7%
- Earnings growth (YoY)
- 948.3%
- Gross margin
- −25.5%
- Operating margin
- −39.5%
- Net margin
- 37.7%
Higher than 90% of US stocks
Higher than 97% of US stocks
Higher than 3% of US stocks
Higher than 18% of US stocks
Higher than 94% of US stocks
- Return on equity
- 55.8%
- Return on assets
- −22.6%
- Dividend yield
- —
Higher than 94% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Moolec Science SA (MLEC) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Moolec Science SA has a market value of $4.5M and an enterprise value of $250.6M.
Revenue in the twelve months to 31 Dec 2024: $7.8M. The latest quarter grew 69.7% year on year.
Net income over the same four quarters: −$8.3M, a −105.7% net margin.
Diluted earnings per share, trailing twelve months: $−27.40.
Free cash flow in the twelve months to 31 Dec 2024: −$7.0M, after $61K of capital spending.
Moolec Science SA spent $0.0 on dividends in the twelve months to 31 Dec 2024.
Trailing P/E: −0.0×; forward P/E: −27.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Moolec Science SA employs 52 people — $151K of revenue per employee.
Data provided by Twelve Data
MLEC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Moolec Science SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about MLEC stock
Is MLEC stock a buy right now?
Of the 1 analysts covering Moolec Science SA, 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Moolec Science SA 3 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MLEC?
As at 14 Sept 2026, Moolec Science SA ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
What is the MLEC stock forecast for 2030?
No analyst covering Moolec Science SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MLEC are extrapolating price history, which says nothing about the business.
How has MLEC stock performed over the past year?
Moolec Science SA returned -66.8% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Moolec Science SA do?
Moolec Science SA is a science-based food ingredient company focused on developing functional ingredients through molecular farming and precision fermentation. Moolec Science SA creates ingredients for food, pet food, animal feed, and dietary supplements by engineering crops such as soy and safflower, as well as using microbial systems, to produce animal-like proteins, nutritional oils, and other bioactive compounds.
About Moolec Science SA.
Moolec Science SA is a science-based food ingredient company focused on developing functional ingredients through molecular farming and precision fermentation. Moolec Science SA creates ingredients for food, pet food, animal feed, and dietary supplements by engineering crops such as soy and safflower, as well as using microbial systems, to produce animal-like proteins, nutritional oils, and other bioactive compounds. Its current product portfolio includes textured soy proteins, safflower-derived oil, meat replacement ingredients, and protein-based formulations designed for use in plant-based and hybrid food applications. The company operates an integrated platform that combines research and development, manufacturing, and regulatory capabilities to support product validation and commercialization across multiple markets. Moolec Science SA serves the alternative protein and specialty ingredients segments of the food industry, where it aims to provide ingredients with animal-like functionality while using plant-based production systems.
CEO Mr. Gaston Paladini M.B.A. · 52 employees · Cayman Islands · https://www.moolecscience.com